Sarepta Therapeutics: A Biotech Stock Navigating Hope and Peril

Sarepta Therapeutics shares continue to experience extreme volatility as promising clinical developments clash with significant safety concerns. The biotechnology firm finds itself at a critical crossroads, balancing encouraging new data presented at the Vienna muscle congress against serious allegations regarding treatment safety and a sweeping corporate restructuring.

The company’s financial landscape reveals a troubling trajectory. Despite a 26% surge last week, Sarepta’s stock has plummeted 81% since the beginning of 2025. This dramatic decline persists despite the company’s radical reorganization plan, which involves eliminating 500 positions and refocusing on siRNA programs. These measures aim to generate approximately $400 million in annual savings, though questions remain about whether this will be sufficient to reverse the downward trend.

Market analysts remain deeply divided... Read more...